These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 32509072)
1. Association of CD44 and CD24 phenotype with lymph node metastasis and survival in triple-negative breast cancer. Zou W; Yang Y; Zheng R; Wang Z; Zeng H; Chen Z; Yang F; Wang J Int J Clin Exp Pathol; 2020; 13(5):1008-1016. PubMed ID: 32509072 [TBL] [Abstract][Full Text] [Related]
2. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma. Chen Y; Song J; Jiang Y; Yu C; Ma Z Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852 [TBL] [Abstract][Full Text] [Related]
3. Decreased expression of autophagy protein LC3 and stemness (CD44+/CD24-/low) indicate poor prognosis in triple-negative breast cancer. Chang SJ; Ou-Yang F; Tu HP; Lin CH; Huang SH; Kostoro J; Hou MF; Chai CY; Kwan AL Hum Pathol; 2016 Feb; 48():48-55. PubMed ID: 26772398 [TBL] [Abstract][Full Text] [Related]
4. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma. Zheng Z; Shao N; Weng H; Li W; Zhang J; Zhang L; Yang L; Ye S Med Oncol; 2015 Jan; 32(1):275. PubMed ID: 25429827 [TBL] [Abstract][Full Text] [Related]
5. CD44 Wang H; Wang L; Song Y; Wang S; Huang X; Xuan Q; Kang X; Zhang Q Oncol Lett; 2017 Nov; 14(5):5890-5898. PubMed ID: 29113223 [TBL] [Abstract][Full Text] [Related]
6. A Systematic Review to Clarify the Prognostic Values of CD44 and CD44 Abdoli Shadbad M; Hosseinkhani N; Asadzadeh Z; Derakhshani A; Karim Ahangar N; Hemmat N; Lotfinejad P; Brunetti O; Silvestris N; Baradaran B Front Oncol; 2021; 11():689839. PubMed ID: 34434894 [TBL] [Abstract][Full Text] [Related]
7. Lack of Androgen Receptor Expression Selects for Basal-Like Phenotype and Is a Predictor of Poor Clinical Outcome in Non-Metastatic Triple Negative Breast Cancer. Riaz N; Idress R; Habib S; Lalani EN Front Oncol; 2020; 10():1083. PubMed ID: 32850312 [No Abstract] [Full Text] [Related]
8. CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma. Lin Y; Zhong Y; Guan H; Zhang X; Sun Q J Exp Clin Cancer Res; 2012 Jul; 31(1):59. PubMed ID: 22762532 [TBL] [Abstract][Full Text] [Related]
9. Prognosis assessment of CD44 Gu J; Chen D; Li Z; Yang Y; Ma Z; Huang G Arch Gynecol Obstet; 2022 Oct; 306(4):1147-1160. PubMed ID: 35435483 [TBL] [Abstract][Full Text] [Related]
10. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN. Wu Y; Sarkissyan M; Elshimali Y; Vadgama JV PLoS One; 2013; 8(10):e78259. PubMed ID: 24167614 [TBL] [Abstract][Full Text] [Related]
11. The expressions of NEDD9 and E-cadherin correlate with metastasis and poor prognosis in triple-negative breast cancer patients. Li P; Sun T; Yuan Q; Pan G; Zhang J; Sun D Onco Targets Ther; 2016; 9():5751-5759. PubMed ID: 27703373 [TBL] [Abstract][Full Text] [Related]
12. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Mylona E; Giannopoulou I; Fasomytakis E; Nomikos A; Magkou C; Bakarakos P; Nakopoulou L Hum Pathol; 2008 Jul; 39(7):1096-102. PubMed ID: 18495204 [TBL] [Abstract][Full Text] [Related]
13. The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. Giatromanolaki A; Sivridis E; Fiska A; Koukourakis MI Med Oncol; 2011 Sep; 28(3):745-52. PubMed ID: 20405247 [TBL] [Abstract][Full Text] [Related]
14. Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer. Nogi H; Suzuki M; Kamio M; Kato K; Kawase K; Toriumi Y; Takeyama H; Fukushima H; Morikawa T; Uchida K Oncol Rep; 2011 Apr; 25(4):1109-15. PubMed ID: 21308353 [TBL] [Abstract][Full Text] [Related]
15. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Ma F; Li H; Wang H; Shi X; Fan Y; Ding X; Lin C; Zhan Q; Qian H; Xu B Cancer Lett; 2014 Oct; 353(2):153-9. PubMed ID: 25130168 [TBL] [Abstract][Full Text] [Related]
16. The Hedgehog signaling pathway is associated with poor prognosis in breast cancer patients with the CD44+/CD24‑ phenotype. Zhao H; Tang H; Xiao Q; He M; Zhao L; Fu Y; Wu H; Yu Z; Jiang Q; Yan Y; Jin F; Wei M Mol Med Rep; 2016 Dec; 14(6):5261-5270. PubMed ID: 27779682 [TBL] [Abstract][Full Text] [Related]
17. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632 [TBL] [Abstract][Full Text] [Related]
18. Relationship of CD44+CD24-/low breast cancer stem cells and axillary lymph node metastasis. Wei W; Hu H; Tan H; Chow LW; Yip AY; Loo WT J Transl Med; 2012 Sep; 10 Suppl 1(Suppl 1):S6. PubMed ID: 23046710 [TBL] [Abstract][Full Text] [Related]
19. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast. Oon ML; Thike AA; Tan SY; Tan PH Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743 [TBL] [Abstract][Full Text] [Related]
20. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]